Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism

Cholesteryl ester transfer protein (CETP) facilitates the transfer of HDL cholesteryl ester to triglyceride-rich lipoproteins (TRL). This study aimed to determine the effects of CETP inhibition with torcetrapib on TRL composition and apoB-48 metabolism. Study subjects with low HDL cholesterol (<4...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of lipid research Ročník 53; číslo 6; s. 1190 - 1199
Hlavní autoři: Diffenderfer, Margaret R, Brousseau, Margaret E, Millar, John S, Barrett, P Hugh R, Nartsupha, Chorthip, Schaefer, Peter M, Wolfe, Megan L, Dolnikowski, Gregory G, Rader, Daniel J, Schaefer, Ernst J
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Elsevier 01.06.2012
Témata:
apolipoprotein
Apolipoprotein B-48 - blood
Apolipoprotein B-48 - metabolism
Cholesterol Ester Transfer Proteins - antagonists & inhibitors
cholesteryl ester transfer protein
Female
Humans
Kinetics
lipoprotein kinetics
Lipoproteins - blood
Lipoproteins - chemistry
Lipoproteins - metabolism
Male
Middle Aged
postprandial metabolism
Quinolines - pharmacology
torcetrapib
Triglycerides
ISSN:1539-7262, 0022-2275, 1539-7262
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Cholesteryl ester transfer protein (CETP) facilitates the transfer of HDL cholesteryl ester to triglyceride-rich lipoproteins (TRL). This study aimed to determine the effects of CETP inhibition with torcetrapib on TRL composition and apoB-48 metabolism. Study subjects with low HDL cholesterol (<40 mg/dl), either untreated (n = 9) or receiving atorvastatin 20 mg daily (n = 9), received placebo for 4 weeks, followed by torcetrapib 120 mg once daily for the next 4 weeks. A subset of the subjects not treated with atorvastatin participated in a third phase (n = 6), in which they received torcetrapib 120 mg twice daily for an additional 4 weeks. At the end of each phase, all subjects received a primed-constant infusion of [5,5,5-(2)H(3)]L-leucine, while in the constantly fed state, to determine the kinetics of TRL apoB-48 and TRL composition. Relative to placebo, torcetrapib markedly reduced TRL CE levels in all groups (≥-69%; P < 0.005). ApoB-48 pool size (PS) and production rate (PR) decreased in the nonatorvastatin once daily (PS: -49%, P = 0.007; PR: -49%, P = 0.005) and twice daily (PS: -30%, P = 0.01; PR: -27%, P = 0.13) cohorts. In the atorvastatin cohort, apoB-48 PS and PR, which were already lowered by atorvastatin, did not change with torcetrapib. Our findings indicate that CETP inhibition reduced plasma apoB-48 concentrations by reducing apoB-48 production but did not have this effect in subjects already treated with atorvastatin.
Bibliografie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1539-7262
0022-2275
1539-7262
DOI:10.1194/jlr.M019570